What changes between them is practical. In perimenopause, cycles are still happening and contraception still matters. After menopause, cycles are finished, and new bleeding becomes a reason to contact a clinician.
Perimenopause is the stretch of reproductive aging that begins when menstrual cycles start to vary persistently and ends at the final menstrual period. It is defined by change, not by a number. A cycle that has run close to the same length for years begins to shorten, lengthen or skip, and the pattern no longer settles back.
The Stages of Reproductive Aging Workshop + 10 staging system divides reproductive aging into stages anchored to the final menstrual period, using bleeding patterns as the primary criteria and hormone measurements as supportive ones 1. Within that framework, an early transition is marked by persistent variability in cycle length, and a late transition by longer gaps where cycles are missed altogether 1.
The reason the transition feels chaotic rather than gradual is what the ovary is doing. Research suggests that hormone concentrations during perimenopause fluctuate widely and unpredictably rather than declining in a smooth line 2. Some cycles still ovulate normally. Others do not. Estrogen can run high in one cycle and low in the next, which is why a person can have heavy bleeding, breast tenderness and hot flushes in the same few months.
That variability is also why perimenopause is often the most symptomatic part of the whole process. The body is not adapting to a steady new level, it is reacting to repeated swings. Symptoms can appear while periods are still regular enough that nobody suspects the transition has started.
Menopause is a single day, the date of the final menstrual period, and it is identified only in hindsight after 12 consecutive months have passed with no bleeding and no other explanation. There is no test on that day, no symptom that announces it, and no way to know at the time that a period is the last one.
This is why the word is used loosely in conversation and precisely in clinic. People say they are going through menopause when they mean perimenopause. Clinically, the 12 month rule is the anchor, and the European Society of Endocrinology clinical practice guideline on menopause and the perimenopause sets out how evaluation and management are approached around that definition 3.
The 12 month window exists because the late transition produces long gaps. Three or four months without bleeding is common before cycles return briefly. Waiting a full year reduces the chance of calling it finished while the ovary still has an occasional cycle left. It also matters for contraception, because a cycle that returns after a long gap can still be an ovulatory one.
One further point of language. Everything after that 12 month mark is postmenopause. A woman is postmenopausal for the rest of her life, which is why some of the health questions that come up in this stage are about the decades that follow rather than about symptoms in the moment.
The cleanest way to separate them is by what defines each stage rather than by how each one feels, because the experiences overlap heavily.
| Stage | What defines it | Common experiences |
|---|---|---|
| Perimenopause (the transition) | Starts with persistent change in cycle length, moves through skipped cycles and long gaps, ends at the final menstrual period 1 | Irregular cycles, heavier or lighter bleeding, hot flushes and night sweats, broken sleep, mood changes, foggy thinking, cycles that still sometimes ovulate |
| Menopause (the point in time) | The final menstrual period, confirmed retrospectively after 12 consecutive months with no bleeding and no other cause 3 | Nothing distinct happens on the day itself, it is recognised looking backwards |
| Postmenopause (everything after) | Every year beyond that 12 month mark | Vasomotor symptoms may persist for years, vaginal dryness and urinary symptoms become more common, bone and cardiometabolic health move to the front of the conversation |
Two things follow from this table. First, perimenopause is the only stage you can be in while still having periods. Second, nobody is ever in menopause for a week or a month, because menopause is a date, not a season. If symptoms are present and periods are still occurring, the stage is perimenopause by definition.
Cycles change because the pool of ovarian follicles shrinks with age, and the feedback loop between the ovary and the brain becomes less stable as a result. Early in the transition, the brain increases its signalling to recruit follicles, and cycles often shorten. Later, recruitment fails more often, ovulation becomes intermittent, and gaps open up.
The bleeding itself reflects what happened in that individual cycle. A cycle without ovulation produces no progesterone, so the uterine lining builds under estrogen alone and sheds unpredictably, which can mean a late, heavy or prolonged bleed. A cycle with a short follicular phase arrives early. Over a year, the pattern can swing between both.
Staging leans on this pattern deliberately. Persistent variability in consecutive cycle length marks the early transition, and an interval of 60 days or more without bleeding marks the late transition in the Stages of Reproductive Aging Workshop + 10 criteria 1. Those are observable facts a person can record without any blood draw at all.
This is the practical argument for tracking. A note of each bleed, its length and its heaviness, kept over six to twelve months, tells a clinician more about where someone sits than almost anything else available. Memory flattens the pattern. A record preserves it, and it also makes it obvious when bleeding has shifted into a pattern worth checking rather than simply changing with the transition.
Most symptoms are shared, but their timing differs, and the heaviest symptom burden tends to sit in the late transition and the first postmenopausal years rather than at the very start. Hot flushes, night sweats, disturbed sleep, mood changes and vaginal dryness all appear across stages, which is exactly why symptoms alone cannot place someone precisely.
The Study of Women's Health Across the Nation followed women through midlife and reported that the menopause transition is associated with changes across multiple systems, including vasomotor symptoms, sleep, mood, bone density and cardiometabolic markers 4. International Menopause Society recommendations on midlife health describe vasomotor symptoms and genitourinary symptoms as core features of this period, with management individualised 5.
Some rough patterns are still useful. Cycle change and the first hot flushes often cluster in the transition while periods continue. Sleep disruption frequently tracks night sweats but can occur without them. Genitourinary symptoms, including vaginal dryness, discomfort with sex and more frequent urinary symptoms, tend to become more prominent after the final period rather than before it, and unlike hot flushes they do not usually settle on their own with time.
Two symptoms deserve their own mention because they are so often dismissed. Foggy thinking and loss of libido are both reported through the transition and into postmenopause, and both have more than one possible contributor, including broken sleep and mood changes. Neither one is proof of a stage, and neither one is something to simply absorb without raising it.
A single FSH result cannot separate perimenopause from menopause because the hormone swings substantially during the transition, so one draw captures one moment rather than a trend. Follicle stimulating hormone is the brain's signal to the ovary. As the follicle pool declines, that signal tends to rise, but during perimenopause it rises and falls repeatedly, cycle to cycle and even within a cycle.
The result is a test that can read high one month and unremarkable the next in the same person, with no change in underlying stage. Staging systems reflect that limitation by treating bleeding patterns as primary and endocrine measurements as supportive 1.
Timing makes it harder still. When FSH is measured in someone who is still cycling, the result depends heavily on where in the cycle the blood was drawn, which is why clinicians who do order it usually specify an early follicular draw. In someone with irregular or absent cycles, there is no reliable point to standardise to.
The honest framing is this. An FSH result is one observation. It may support a picture that age, cycle history and symptoms have already painted, and it carries more weight at younger ages where confirming an early transition changes care. It cannot, on its own, announce which stage someone is in. Lab reference ranges also vary by laboratory, age and sex, so the interpretation belongs with the clinician reviewing the whole picture.
Anti-Mullerian hormone tracks the remaining ovarian follicle pool and declines as that pool shrinks, which makes it a better marker of ovarian reserve than of current stage. It is more stable across a cycle than FSH, which is why it gets attention as a possible predictor.
A systematic review of anti-Mullerian hormone for the diagnosis and prediction of menopause found that it carries information about the timing of menopause, while predictive accuracy for an individual woman remains limited 6. In plain terms, studies indicate the marker shifts the odds rather than setting a date 6.
That distinction matters for how the result should be used. A low value in a woman in her late forties with changing cycles mostly confirms what the cycle history already shows. The same value does not tell her whether her last period will arrive next year or in four years. Expecting a calendar from this test leads to disappointment or to decisions made on false precision.
Where it has more practical weight is at younger ages, in fertility planning, or when there is a reason to ask whether ovarian reserve is lower than expected for age. Those are conversations with a clinician who can look at the result alongside cycle history, past surgery, family history and current symptoms. On its own, a number from an ovarian reserve test answers a narrower question than most people assume it does.
Clinicians rely mainly on three things, age, cycle history and symptom pattern, because together they identify the stage more reliably than any single hormone value. Bleeding patterns are the backbone of formal staging, with endocrine measures used in a supporting role 1.
Age sets the prior probability. In a woman in her late forties or fifties with new cycle irregularity and hot flushes, the explanation is usually the transition, and testing adds little. Below the mid forties, the threshold for investigation drops, because an early or premature loss of ovarian function changes long term care and deserves a proper evaluation rather than reassurance. The European Society of Endocrinology guideline on menopause and the perimenopause sets out how this evaluation is structured 3.
Cycle history does the heavy lifting. How long cycles used to run, when they started varying, how long the longest recent gap has been, and whether bleeding has become heavier or prolonged. Symptom history fills in the rest, including hot flushes, night sweats, sleep, mood, vaginal and urinary symptoms, and how much each one interferes with daily life.
Testing enters when the picture is unclear, when symptoms could plausibly come from something else, or when age makes the transition a less likely explanation. It is also worth remembering that bloodwork answers questions about the whole person, not just about staging. Fatigue, low mood, weight change and poor sleep are not specific to this stage, and ruling other contributors in or out often changes what happens next.
The transition lasts for years rather than months in most people, but the length varies widely between individuals, and it is only measurable in retrospect once the final period has passed. Nobody can be told at the start how long their own transition will run.
What can be said with more confidence is the shape. The early part, marked by variable cycle length, tends to be longer and less dramatic. The late part, marked by long gaps between bleeds, is shorter and usually carries the heaviest symptom load. Longitudinal follow up of women through midlife has described symptoms that persist well beyond the final period rather than stopping at it 4.
Two expectations are worth adjusting. The first is that symptoms end when periods do. For many people, vasomotor symptoms continue into postmenopause, and genitourinary symptoms often begin or worsen there. The second is that progress is linear. Cycles can return after a long gap, symptoms can quiet for months and come back, and none of that means something has gone wrong.
Because the duration cannot be predicted, planning around symptom impact makes more sense than planning around an end date. The question that is actually answerable is whether current symptoms are interfering with sleep, work, mood or relationships now, and what options exist for that. Waiting it out is a reasonable choice. It should be a chosen one rather than a default.
Foggy thinking is a common and recognised complaint during the menopause transition, and it is usually described as difficulty with word finding, concentration and short term recall rather than a loss of overall ability. A clinical guide on brain fog in menopause addresses how cognitive complaints in this period are assessed and discussed with patients 7.
Several contributors usually overlap. Night sweats fragment sleep, and fragmented sleep degrades attention and memory the next day. Mood changes affect concentration independently. Hormonal fluctuation adds its own layer. Because these interact, the symptom rarely has one clean cause, and untangling them is part of what a careful history is for.
What helps in practice is separating the strands. If sleep is broken by night sweats, the sleep problem and the vasomotor symptom are the same problem. If mood has shifted, that deserves direct attention. If thyroid function, iron status or vitamin B12 have never been checked, those are worth reviewing, because fatigue and poor concentration are not specific symptoms. Any persistent or worsening cognitive change, particularly one that affects daily function, is worth discussing with a clinician rather than filing under the transition.
After the final period, the conversation shifts from symptom management alone to longer term health, because the hormonal environment is now stable at a new level rather than fluctuating. Bone, cardiometabolic health and genitourinary tissue all become more prominent concerns.
Follow up of women across midlife found that the menopause transition is associated with changes in bone mineral density, body composition and cardiovascular risk markers, alongside the symptoms people notice directly 4. International Menopause Society recommendations on midlife health cover these longer term considerations as part of overall care in this stage rather than as separate issues 5.
Genitourinary symptoms behave differently from hot flushes. Vaginal dryness, discomfort with sex and urinary symptoms tend to persist or progress without attention rather than settling with time, which is why they are raised specifically in postmenopausal care. They are also underreported, often because people assume nothing can be done.
The practical response is unglamorous and well established. Resistance training and adequate protein support muscle and bone. Attention to blood pressure, glucose, lipids and body composition becomes more valuable, not less. Sleep and alcohol both influence vasomotor symptoms for many people. None of this is specific to menopause, but the stage is a sensible moment to review it properly, with a clinician looking at measured values rather than assumptions.
Any bleeding after menopause has been confirmed, meaning after 12 full months without a period, is worth discussing with a clinician promptly. That is the clearest rule in this whole topic. Postmenopausal bleeding is not assumed to be part of the transition, because the transition has already ended.
During perimenopause the picture is less clean, since irregularity is expected. Even so, several patterns warrant a visit rather than watchful waiting. Bleeding that is much heavier than usual or soaks through protection quickly. Bleeding that lasts considerably longer than a normal period. Bleeding between periods. Bleeding after sex. Cycles that suddenly become very frequent. New pelvic pain alongside a change in bleeding.
The reason to check is not that these always indicate something serious, because often they do not. It is that the causes are treatable when identified and that the transition is a convenient explanation that can delay a useful evaluation. Anaemia from prolonged heavy bleeding is also common enough to be worth considering, and it produces fatigue and breathlessness that get attributed to hormones instead.
Bringing a written record helps. Dates, duration, heaviness and anything that coincided with the change give a clinician something concrete to work with. Never ignore a result or a symptom because it seems to fit the expected pattern. Fitting the pattern and being explained by it are different things.
Options range from sleep, exercise and alcohol adjustments through to prescription care, and which ones are appropriate is a decision a licensed provider makes after evaluating the individual. There is no single answer that applies across stages, symptoms and medical histories.
Non prescription steps are worth taking seriously because they address several symptoms at once. Consistent sleep timing, a cooler bedroom, regular resistance and aerobic training, and attention to alcohol intake all influence sleep quality and vasomotor symptoms for many people. These are not a substitute for care when symptoms are severe, but they rarely conflict with anything else.
For moderate to severe symptoms, hormone therapy is one of the options a clinician can discuss, and International Menopause Society recommendations describe management of midlife health and menopause as individualised to the person's symptoms, risk profile and preferences 5. The European Society of Endocrinology guideline covers evaluation and management across menopause and the perimenopause in similar terms 3. Non hormonal prescription options also exist. No dose, schedule or product belongs in an article, because the decision to start, stop or change any treatment belongs to a licensed provider after a proper evaluation of history, risk factors and current symptoms.
What a reader can usefully bring to that conversation is specificity. Which symptoms are worst, how they affect daily life, what has already been tried, personal and family medical history, and what outcome would count as an improvement. That turns an open ended appointment into a focused one.
Because the symptoms of this stage overlap with several other common causes, a broader look at bloodwork usually tells a more complete story than hormone values alone. Fatigue, low mood, poor concentration, hair changes and weight shifts are not specific to reproductive aging.
Markers a clinician may review alongside the clinical picture include thyroid function, iron and ferritin, vitamin D, vitamin B12, fasting glucose and HbA1c, a lipid panel, and liver and kidney function. Heavy or prolonged bleeding makes iron status particularly relevant. Cardiometabolic markers gain importance in this stage given the changes observed across the menopause transition in midlife follow up 4. Body composition is also worth measuring rather than estimating from the scale.
FitScript runs 150+ biomarkers tested per year and has Atlas, its AI health advisor, interpret the results against a member's history, with any treatment decision made by a licensed provider after review. The value of repeat testing in this stage is that it shows direction. One FSH value is a snapshot of a fluctuating system, whereas a trend across several markers over time is far more informative.
Standard lab reference ranges vary by laboratory, age and sex, so a value flagged on one report may read differently on another. Interpretation belongs to a clinician who can place the number next to the symptoms, the cycle history and the rest of the panel. This article is educational and is not medical advice.
It is time when symptoms interfere with daily life, when bleeding changes in the ways described above, or when the transition seems to be starting earlier than expected for age. Discuss your results, your symptoms and any treatment option with a clinician or licensed provider before acting on them.
A few situations deserve a faster appointment. Any bleeding after 12 period free months. Heavy bleeding with fatigue or breathlessness. Symptoms that appear before the mid forties, because an earlier transition changes long term care and should be properly evaluated rather than assumed. Mood changes that feel out of proportion or persistent. Cognitive changes that are worsening rather than fluctuating.
It is also reasonable to book an appointment simply because symptoms are wearing you down, with no red flag at all. Severity, not stage, is the thing that determines whether care is worth discussing. Many people wait because they expect to be told it is normal, and normal and untreatable are not the same thing.
Go in with a cycle record, a short symptom list ranked by impact, your medical and family history, and a clear sense of what you want to change. That makes the stage question much easier to answer, and it moves the conversation past labels and on to what actually helps.
If foggy thinking is the symptom that bothers you most, the guide to brain fog in perimenopause goes deeper on what contributes to it and how it is assessed. For changes in desire and sexual comfort through this stage, see libido for menopause. And if you want to understand what a provider evaluation covers before you book one, the overview of hormone care for women explains how those decisions are approached.
Count backwards from your last period. If you have had any bleeding in the past 12 months, you are in perimenopause by definition, even if symptoms are severe. Once 12 consecutive months have passed with no bleeding and no other cause, menopause is considered confirmed and you are postmenopausal from that point on.
Yes. Cycles become irregular during the transition, but ovulation can still occur, including after several months without a period. Contraception needs during this stage are worth raising with a clinician, who can advise on how long it should continue based on your age and cycle history.
Not on its own in most cases. Hormone levels swing widely during the transition, so one draw reflects a single moment rather than a stage. Clinicians mainly use age, cycle history and symptoms, and may add bloodwork when the picture is unclear or when symptoms begin earlier than expected for age.
Yes, the 12 month clock restarts from that bleed, because a cycle has occurred. That is exactly why the rule uses a full year rather than a few months. If the bleeding was unusual in any way, such as very heavy or prolonged, mention it to a clinician rather than simply resetting the count.
Often not. Hot flushes and night sweats can continue for years after the final period, and vaginal dryness and urinary symptoms frequently become more noticeable afterwards rather than before. Persistent symptoms at any stage are worth raising with a clinician, since options exist and severity matters more than which stage you are in.
The transition involves hormone levels that rise and fall unpredictably rather than settling at a steady level. Many people find the swings harder to live with than the lower, stable levels that follow. This is also why symptoms can vary a lot from month to month during perimenopause.
An earlier transition is worth a proper evaluation rather than reassurance, because it changes long term health planning. Book an appointment and bring a record of your cycles and symptoms. A clinician can decide what testing is appropriate and what follow up makes sense for your age.
Bring a record of your recent cycles with dates, duration and heaviness, a short list of symptoms ranked by how much they affect daily life, your medical and family history, and anything you have already tried. Being specific about what you want to improve helps the clinician focus the conversation and decide what, if anything, to test.